Based primarily in Kazan, Tatarstan, Russia, the Kazan State Medical University is a federal university made up of nine faculties. The university got the license on 6 March 1994 by the State Committee of the Russian Federation of Higher Education.

During the past decade, Kazan State Medical University conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Kazan State Medical University" are "Colitis, Ulcerative" (1 trials), "Crohn's Disease (CD)" (1 trials) and "Post Herpetic Neuralgia" (1 trials). Many other conditions were trialed in "Kazan State Medical University" in a lesser frequency.

Most popular intervention types in "Kazan State Medical University" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Pregabalin" (1 trials), "Vedolizumab" (1 trials), "Vedolizumab IV" (1 trials) and "placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kazan State Medical University" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Kazan State Medical University". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Kazan State Medical University, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Kazan State Medical University, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".